Nanogen Recognomics Gmbh

Evonik Roehm Gmbh

Evonik Operations Gmbh

Other

Siemens Aktiengesellschaft

Degussa Aktiengesellschaft

Sanofi-aventis

Nanogen, Inc.

Evonik Rohm Gmbh

Aventis Research & Technologies Gmbh & Co Kg

Aventis Research & Technologies Gmbh & Co.

Windhab, Norbert

Brücher, Christoph

Norbert Windhab

Christian Miculka

Tilmann Brandstetter

Gerhard Burdinski

Markus Schweitzer

Benedikt Hartwig

Thomas J Onofrey

Charles Greef

Daguang Wang

John R Havens

Stefan Scherer

Andrea Engel

Melanie Liefke

Anne Benedikt

Christoph Brücher

Hans-Ulrich Hoppe

Hans-Ulrich Petereit

Klaus Abraham-Fuchs

Arne Hengerer

Matthias Seiler

Rosario Lizio

Andreas Karau

Michael Damm

Kevin Burton

Michael Gottschalk

Julia Lyubina

Peter Niepoth

Manfred Stickler

Thomas Wagner

Gerhard Quinkert

Albert Eschenmoser

Stefan Raddatz

Juan Tome Alcalde

Greg Gosch

Tom Tice

Jessica Müller-Albers

Kieran T Gallahue

Donald Lupo

Christian Meier

Mariola Fotin-Mleczek

Rainer Fischer

James P O'Connell

Martin Schilling

Richard R Anderson

Erna Roth

Matthias Germer

Guenter Schmitt

Günter Schmitt

Stefan Kienle

Andreas Gryczke

Ruediger Alexowsky

Ines Ochrombel

Michael D Fiechtner

Gerhard Geipel

Bodo Speckmann

Mario Gomez

Paul Joseph Spencer

Peter Hölig

Hans-Joachim Stiller

Steffen Junginger

Rima Jaber

Axel Schroeder

Jens Daufenbach

Jochen Müller-Ibeler

Jochen Müller

Jill M Orwick

Eberhard Schneider

Marc Pignot

James P O'Conell

Maria Del Pilar Ansuategui Panzano

Jean-Luc Herbeaux

Matias Javier Vara Carrera

Christian Kessler

Jochen Bodem

Carsten Dentler

Rüdiger Alexowsky

Maria Steinke

Roland Brock

Hansjoerg Hufnagel

Angela Olf

Juan Tome-Alcalde

Susanne Ullrich

Steffen Kistner

Hansjorg Hufnagel

Maria Del Ansuategui Panzano

Axel SCHRÖDER

María Del Pilar Ansuategui Panzano

Matías Javier Vara Carrera

A method of unambiguous identification and authentication of products for the purpose of better recognition of product forgeries and controlling product piracy, including applying to/into the product an identification substance admixture which contains paramagnetic phases or identifying a product which contains an identification substance admixture containing paramagnetic phases and has an ESR fingerprint spectrum that permits unambiguous identification of the product. Such an ESR fingerprint spectrum is easily measurable, but can be copied or forged only with difficulty. The method relates to an individualizable 'femto tag' for femto ledgers and forms an important interface for what are known as “Internet of Things” (IOT).

Unique identification and authentication of products

A preparation containing a mixture of at least one phospholipid, and at least one fatty acid salt of a cation with an anion derived from a fatty acid. A method for preparing such preparation and the use of such preparation to provide polyunsaturated fatty acids to cells, tissues, organs or organisms, for example in the field of cell and tissue culture, organ preservation, human or animal nutrition, or cosmetics.

Preparation comprising a dispersion of phospholipids and fatty acid salts

A composition may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Paramyxoviridae family and wherein the composition includes an extract of black currants and bilberries. The composition may contain an extract from black currants and bilberries in a weight ratio in a range of from 0.5:1 to 1:0.5. The extract may be an alcoholic extract, such as a methanol extract. The composition may be administered to the subject 1 to 10 oral dosages of at least 80 mg anthocyanins each per day, preferably 3 to 6 oral dosages of at least 80 mg anthocyanins each per day. The subject may not have received a measles vaccination or have previously been exposed to the measles virus.

Preparations containing berry extracts for use in the prophylaxis and/or treatment of viral infections caused by Paramyxoviridae

A body has multiple phases, which have different electron spin resonance spectra that do not result from the simple combination of the ESR spectra of each individual phase.

Masking and subsequently visualising ESR signals using the combination of two materials

An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.

Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)

A process for preparing a powder, which includes one or more human coagulation factor proteins and a lactic acid polymer, involves mixing and dispersing a lactic acid polymer with a particle size din the range 0.1-2 &#x3bc;m and the one or more human coagulation factor proteins in water. The dispersion is dried, and the resulting dried mass is compressed. The resulting compressed dried mass is comminuted to a powder with a particle size din the range of more than 0.5 and up to 5 &#x3bc;m.

Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance.

Human lactoferrin derived peptide for use as an antigen masking agent

The subject matter of the invention is a detector system for detecting magnetic bodies in the human organism, which comprises at least two sensor assemblies, wherein each sensor assembly has one, two or three anisotropic magnetic resistance sensors, of which the axes of weak magnetization point in different directions in pairs, and each sensor assembly has a spacing of 0.5 to 50 cm from the sensor assembly or the other sensor assemblies, and at least two sensor assemblies are tilted at an angle of 0 to 45&#xb0; with respect to one another, and in addition a method for detecting the magnetic flux produced by a magnetic body in the human organism, and the use of the detector system according to the invention for detecting swallowed magnetic bodies and the disintegration of the same in the digestive system.

Detection system for detecting magnetic objects in the human organism

The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterized in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another.

Drug-delivery systems

A peptide having an amino acid sequence containing at least eight consecutive amino acids of the human lactoferrin protein or of the bovine lactoferrin protein. The peptide is suitable as a cell-penetrating peptide. A complex of the peptide and a cargo molecule non-covalently bound to the peptide. The cargo molecule may be a nucleic acid, an amino acid, a peptide, a protein, a carbohydrate, a lipid, or a small molecule. A method of penetrating or transfecting a cell using the complex.

Peptides useful as cell-penetrating peptides

The invention relates to an oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles, wherein the dosage form has an at least two phase composition, wherein the phases can dissolve in the body after oral administration due to their formulation and the magnetizable particles are bound in formulation auxiliary substances and are present in a magnetized state, wherein the magnetized particles are present in at least two phases of the dosage form and generate magnetic fields, wherein these phases dissolve at different times in the body after oral administration, and wherein the magnetic field strength with respect to time, position and movement in the body is acquired using a detection system and can be evaluated using a computer-based evaluation system.

Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles

The invention relates to a pharmaceutical or nutraceutical formulation comprising a core, comprising an active pharmaceutical or nutraceutical ingredient, a penetration promoter and a bioavailability promoting agent, and a polymeric coating for the gastrointestinal targeted release of the active ingredient, characterized in that the bioavailability promoting agent is a pharmaceutically acceptable inhibitor of proteolytic enzymes, which increases the oral bioavailability of the active ingredient by a factor of at least five, compared to a corresponding formulation without the bioavailability promoting agent.

Pharmaceutical or neutraceutical formulation

Compounds relating to attachment chemistries for binding biomolecules to a substrate surface are described. These include compounds of the following structure: The biomolecule includes a single nucleic acid, oligonucleotides, polynucleotides, DNAs, RNAs, proteins, peptides, enzymes, antibodies, CNAs (cyclohexyl nucleic acids), p-MeNAs (methyl or methoxy phosphate nucleic acids), peptide nucleic acids (PNAs), and pyranosyl RNAs (p-RNAs).

Biomolecules having multiple attachment moieties for binding to a substrate surface

Methods of binding biomolecules to a substrate are provided that include contacting the biomolecule with a branched linking moiety to form a branched linking structure. The branched linking structure is then contacted with a binding moiety on the substrate to form a coupled substrate binding structure, thereby binding the biomolecule to the substrate. The biomolecule may contain a Lewis base or a nucleophile to react with a Lewis acid or electrophile in the branched linking moiety. Alternatively, the biomolecule may contain a Lewis acid or electrophile that can react with a Lewis base or nucleophile in the branched linking moiety. Additionally, the biomolecule can be bound to the substrate through a covalent or non-covalent bond.

Growing community of inventors

Hofheim, Germany

Norbert Windhab